Application and mechanistic research of novel therapeutic strategies in cisplatin-resistant small cell lung cancer - PubMed
4 hours ago
- #Cisplatin resistance
- #Small cell lung cancer
- #Targeted therapy
- Small cell lung cancer (SCLC) initially responds to cisplatin-based chemotherapy but develops rapid resistance.
- Seven key mechanisms of cisplatin resistance in SCLC include altered drug uptake, dysregulated apoptosis, enhanced DNA repair, tumor microenvironment interactions, metabolic adaptations, subtype transitions, and epigenetic changes.
- Targeted therapies like MDR inhibitors and Bcl-2 inhibitors can restore sensitivity but face toxicity and efficacy limitations.
- Immunotherapy (PD-1/PD-L1, CTLA-4 inhibitors) shows potential but is hindered by the immunosuppressive tumor microenvironment.
- PARP inhibitors and novel chemotherapeutic agents offer alternative treatments, with combination therapies showing promise.
- Biomarker-guided strategies may optimize personalized therapy for cisplatin-resistant SCLC patients.
- Future research should integrate mechanistic insights with emerging therapies to develop more effective treatments.